Trade type: LONG Status: CLOSED May 28, 2026
| Price | Date | |
|---|---|---|
| Entry | $25.50 | May 23, 2026 (Fri) |
| Exit | $26.21 | May 28, 2026 (Wed) |
| P&L | +$0.71 / +2.78% | 3 trading days |
The Contrarian Setup
The consensus on Pfizer entering 2026 was uniformly negative: COVID revenue collapse, Paxlovid sales decline, overpriced Seagen acquisition, bloated cost structure. The stock declined from $50+ in 2022 to the mid-$20s — over 50% in four years. At $25.50, PFE was trading at 8–9x forward earnings with a 6.6% dividend yield on $60+ billion in annual revenue.
I disagreed with the current consensus, not the historical one. The revenue cliff already happened and was already priced. What was mispriced in May 2026:
- Cost resets ahead of schedule. Pfizer's $4+ billion savings program is executing faster than guided.
- Seagen contributing. Padcev and the oncology pipeline are beginning to offset the COVID revenue gap.
- Base too punitive. 8–9x forward earnings on a company this size, with this dividend, assumes permanent impairment. It's not permanent.
Entry: $25.50 on May 23. Stop: $24.50.
Trade Path
| Date | PFE | Move |
|---|---|---|
| May 23 — Entry | $25.50 | — |
| May 27 — Close | $25.85 | +$0.35 / +1.4% |
| May 28 — Exit | $26.21 | +$0.36 / +1.39% on the day |
The decisive signal came on May 28: PFE gained +1.39% on a day when the broader market was negative, SOXX fell −1.07%, and financial stocks were under rotation pressure. PFE moved against the tape. That is the definition of stock-specific buying — someone is accumulating PFE at these levels regardless of macro noise.
Why I Closed Today
I'm closing all seven positions simultaneously today. PFE is the trade I'm most tempted to hold — the +1.39% on a weak tape suggests the thesis is beginning to be recognised by the market. But the discipline of a clean weekly close applies equally to my best trade and my worst.
The contrarian pharma thesis worked on a short-horizon swing. +2.78% in three days on a beaten-down large-cap is a strong outcome. I'll re-enter on a pullback toward $25.50 if the cost-reset and Seagen narrative continues to develop.
Closed at $26.21. Net gain: +$0.71 per share, +2.78%. Second-best return in the May 25–28 book after SMCI.